Skip to main content
SpringerLink
Log in

Flibanserin for HSDD: little benefit, increased nausea and dizziness

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Jaspers L, et al. Efficacy and Safety of Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Women: A Systematic Review and Meta-Analysis. JAMA Internal Medicine : 29 Feb 2016. Available from: URL: http://dx.doi.org/10.1001/jamainternmed.2015.8565

    PubMed  Google Scholar 

  2. Woloshin S, et al. US Food and Drug Administration Approval of Flibanserin: Even the Score Does Not Add Up. JAMA Internal Medicine : 29 Feb 2016. Available from: URL: http://dx.doi.org/10.1001/jamainternmed.2016.0073

    PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Flibanserin for HSDD: little benefit, increased nausea and dizziness. Reactions Weekly 1592, 9 (2016). https://doi.org/10.1007/s40278-016-15437-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-016-15437-z

Search

Navigation